Synthorx, Inc.

Once seen as the next big thing in cancer, cytokine-based therapies lost their shine after numerous trial flops, but Synthekine is among a number of companies that believe they can succeed with a ne

Sanofi 's shifting of R&D resources away from cancer to cement its industry leadership in immunology and inflammation is a sensible move but the company will continue to advance some interesting early

Capstan Therapeutics Inc. and Engrail Therapeutics are among the latest companies to raise venture capital mega-rounds of $100m or more as the deluge of large private financings early in 2024 coinc

After a six-month search to find a permanent replacement for research chief John Reed, Sanofi has dipped into the venture capital sector and appointed Houman Ashrafian as its new head of R&D, effect